Koen De Geest, MD

Articles:

Tate Thigpen J, Blessing JA, De Geest K, Look KY, Homesley HD; Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 May;93(2):336-9.

Behbakht K, Lynch A, Teal S, De Geest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004 Dec;104(6):1355-61.

Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, De Geest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Oct; 99(1):71-9.

Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005 Oct 1;23(28):7105-13.

Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K, Domann FE. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol. 2006 Aug;102(2):319-24.

Ahmed A, De Geest K, Van Natta T, Sorosky J. Metastatic choriocarcinoma to the lung coexistent with a viable pregnancy. Int J Gynaecol Obstet. 2006 Jul;94(1):56-7.

Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, De Geest K, Sood K, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun. 2008 Jan;22(1):65-73.

Rose PG, De Geest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Nov;107(2):274-9.

Lutgendorf SK, Lamkin DM, De Geest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun. 2008 Aug;22(6):890-900.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of interleukin-8 gene silencing with liposome-

encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 5;100(5):359-72.

Hensley ML, Blessing JA, De Geest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008 Jun;109(3):323-8.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008 Jun 1;14(11):3372-9

Morgan MA, Darcy KM, Rose PG, De Geest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ; Gynecologic Oncology Group. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep; 110(3):329-35.

Watts GS, Futscher BW, Holtan N, De Geest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008 Sep 30;1:47.

Ahmed A, Zamba G, De Geest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002. Gynecol Oncol. 2008 Oct; 111(1):35-40.

Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, De Geest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008 Oct 10;26(29):4820-7.

Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, De Geest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008 Nov 1;14(21):6839-46.

Lutgendorf SK, De Geest K, Sung CY, Arevalo JM, Penedo F, Lucci J 3rd, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun. 2009 Feb; 23(2):176-83.

Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, De Geest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar; 112(3):543-52.

Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, De Geest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar 1;115(5):1021-7.

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305.

Aghajanian C, Blessing JA, Darcy KM, Reid G, De Geest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2010 Jan 1;28(1):149-53. 2009 Aug 25. [Epub ahead of print]

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010 Jan 1;28(1):149-53. Epub 2009 Nov 16.